UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy

Geretti, AM; Harrison, L; Green, H; Sabin, C; Hill, T; Fearnhill, E; Pillay, D; ... UK Collaborative Grp HIV Drug Resi, ; + view all (2009) Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy. CLIN INFECT DIS , 48 (9) 1296 - 1305. 10.1086/598502.

Full text not available from this repository.

Abstract

Background. It has been proposed that subtype-related human immunodeficiency virus type 1 (HIV-1) variability may influence virologic and immunologic responses to highly active antiretroviral therapy ( HAART). Studies to date, however, have described treatment outcomes predominantly in persons with subtype B infection or compared subtype B with diverse non-B subtypes grouped together.Methods. With use of data from the linked UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study databases, time to viral load undetectability (viral load, < 50 copies/mL), time to virologic rebound (viral load, > 1000 copies/mL), and increases in the CD4 cell count were compared for a median of 39 months (interquartile range, 23-67 months) in drug-naive patients infected with subtype B (n = 1550), subtype C (n = 272), subtype A (n = 66), circulating recombinant form AG (n = 57), or subtype D (n = 41) disease who started HAART.Results. Overall, 1906 (90%) of 2116 patients achieved viral load undetectability within 12 months after they started HAART, of whom 335 (18%) subsequently experienced virologic rebound. In adjusted analyses, viral load suppression occurred more rapidly in patients infected with subtype C (hazard ratio, 1.16; 95% confidence interval, 1.01-1.33; P = .04) and subtype A (hazard ratio, 1.35; 95% confidence interval, 1.04-1.74; P = .02) relative to subtype B infection. The virologic rebound occurred marginally more rapidly in patients with subtype C infection (hazard ratio, 1.40; 95% confidence interval, 1.00-1.95; P = .05), but the hazard of virologic rebound was similar with other subtypes. Although persons with subtype B infection showed higher baseline CD4 cell counts and maintained the advantage throughout therapy, CD4 cell count recovery occurred at similar rates with all subtypes.Conclusions. Patients infected with prevalent non-B subtypes were as likely to achieve viral load suppression as persons infected with subtype B and showed comparable rates of CD4 cell count recovery. HAART achieves excellent outcomes regardless of the infecting subtype.

Type: Article
Title: Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy
DOI: 10.1086/598502
Keywords: MULTICENTER AIDS COHORT, NON-B SUBTYPES, DRUG-RESISTANCE, PROTEASE INHIBITORS, UNITED-KINGDOM, CONTAINING REGIMENS, INFECTED PATIENTS, AFRICAN PATIENTS, TYPE-1 SUBTYPE, BASE-LINE
UCL classification: UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health Care > Infection and Population Health
?? G10 ??
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > MRC Clinical Trials Unit at UCL
URI: http://discovery.ucl.ac.uk/id/eprint/144803
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item